High-Level Forum on the Silver Economy Announces Bayer AG as Strategic Partner

Bayer AG CEO Werner Baumann to address the need for innovative healthy aging strategy

New York, NY (July 3, 2019) – The Global Coalition on Aging (GCOA), the global business voice on aging, and the Finnish EU Council Presidency, which commences in July 2019, have joined together to organize the High-Level Forum on the Silver Economy. It is the first-ever conference focused on business and government leadership, on a global basis, to reimagine aging. The Forum will take place in Helsinki, Finland, on July 9-10 at the iconic Finlandia Hall. One of the core issues to be explored at the Forum is innovations for healthy aging.

Bayer AG, a multinational pharmaceutical and life sciences company, joins the Forum as a Strategic Partner. Werner Baumann, Chief Executive Officer of Bayer AG, will be a featured speaker at the conference. Baumann will discuss the need for innovation in advancing a healthy aging agenda.

“Today’s growing health and economic challenges related to aging population require innovative solutions from stakeholders all across society” said Baumann. “As a leading life sciences company we are striving to find solutions for unmet medical needs to tackle  age-related diseases. Ultimately, we want to continue to make a meaningful contribution to society, enabling a healthier and more active aging for all.”

The global population over 60 is set to double between today and 2050, from 1 billion to 2 billion. While longevity is on the rise, birth rates are on a precipitous decline, leading to the rapid aging of society — trends never before experienced in human history. The demands for public policy change aligned to one of the most consequential megatrends of our era is matched by the opportunities for business strategies leveraging the $15 trillion silver market.

An invitation-only event, the Forum will draw approximately 500 delegates, including government leaders from around the world, CEOs from Fortune 100 companies, and thought leaders from academia and non-governmental organizations to offer solutions and innovative ideas that position the aging of society as a lever for growth, rather than a drain on society. Viewing population aging through this lens is good for citizens of all ages—imagining how we might behave when 100-year lives are the norm across the globe.

“Healthy aging must be a central component of any company’s business strategy and any country’s policy decision-making process,” said Dr. John Beard, former Director of Ageing and life Course at the World Health Organization and Chair of the Global Coalition on Aging Advisory Council. “Silver Economy Forum presents the first-ever global gathering of business and government leaders to provide real and practical solutions that leverage our aging population for growth.”

The Silver Economy Forum’s two-day event will:

  • Illuminate the silver economy business opportunity. With the world’s 60+ population doubling between now and 2050, today’s 60+ spending power of US$15 trillion will grow even stronger. This group is larger and healthier and more active than ever before, so how will companies serve and leverage this untapped market?
  • Define strategies for the multi-generational workforce.All employers are faced with critical talent issues as the workforce ages and for the first time ever there are five generations in the same workplace. The very concept of retirement at a pre-determined age is now obsolete. How can employers navigate and grow in this changing environment?
  • Set the policy agenda.  Strategic planning through an aging lens will be the most important consideration for government policy in the coming decades. From health and wellness to caregiving, and from NCDs and conditions of aging to social and financial benefits, aging will be the central driver of policy reform. How will national policies adapt, and what role will business play?

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. Bayer is a member of the Global Coalition on Aging. For more information, go to www.bayer.com.

About the Global Coalition on Aging
The Global Coalition on Aging aims to reshape how global leaders’ approach and prepare for the 21st century’s profound shift in population aging. GCOA uniquely brings together global corporations across industry sectors with common strategic interests in aging populations, a comprehensive and systemic understanding of aging, and an optimistic view of its impact. Through research, public policy analysis, advocacy, and strategic communications, GCOA is advancing innovative solutions and working to ensure global aging is a path to health, productivity and economic growth.

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

GCOA Sign-on Letter to Governor Spanberger: Consequences of Importing Federal Price Caps on Virginians’ Access to Medicine & Healthy Aging Opportunities

Dear Governor Spanberger: We, the undersigned organizations, bring deep, on‑the‑ground experience serving older Americans, patients managing complex and chronic conditions, and their caregivers across Virginia and nationwide. We also have a clear understanding of which policies and programs are effective and where they fall short.

New Report Summarizes State of Expert Opinions on Japan’s Adult Vaccine Policy as Population Shifts Older

The Global Coalition on Aging (GCOA), Health and Global Policy Institute (HGPI), and the Asia-Pacific Consortium for Healthy Aging and Adult Immunization (AP-CHAAI) today announced the launch of Strengthening Vaccine Policy for Healthy Aging and Economic Growth in Japan, a landscape analysis examining the state of vaccine policy in super-aging Japan. Based on a comprehensive review of over 100 policy documents, recommendations, reports, academic papers, and gray literature articles, the report, which was funded by GSK, summarizes the latest academic research and policy discourse around adult vaccines.

WSJ Letter to the Editor: How Flu Vaccine Policies Affect the Economy

Your editorial “Vinay Prasad’s Vaccine Kill Shot” (Review & Outlook, Feb. 12) points out that a recent decision by Mr. Prasad, the leader of the Food and Drug Administration’s vaccine division, will have negative consequences. Mr. Prasad’s decision to reject Moderna’s flu vaccine without even reviewing it is even worse than you describe. Denying us a new, innovative flu vaccine is horrible health policy. Innovation is at risk because, as Moderna’s CEO has said, if the largest market is off limits, investments won’t be made. But the decision will also have economic consequences. Investment in preventive health is critical as our population ages. In its April 2025 World Economic Outlook report, the International Monetary Fund dedicated an entire chapter to the need for healthier longevity as the global population ages.

Joe Biden’s ‘Cancer Moonshot’ May be Derailed by New Policies, Including His Own

For almost a decade, President Biden has championed a bold “cancer moonshot” — an initiative he first launched in 2016, revived early in his administration, and reiterated during this year’s State of the Union. It is a laudable goal, especially for an aging nation where cancer and chronic disease are on the rise. There’s just one problem: Recent federal and state policies are poised to derail the incredible progress made in oncology since 2016. A rash of policies now threatens to limit access and slow progress towards new breakthroughs.

Global Coalition on Aging, Leading G7 Government Officials, Call for Incentivized Antibiotic Innovation

The Global Coalition on Aging (GCOA), in partnership with the Japanese Pharmaceutical Manufacturer’s Association (JPMA), and public health leaders call on G7 governments to fund pull incentives and make “fair share” investments in antibiotic innovation to fight the global antimicrobial resistance (AMR) crisis. GCOA, JPMA, and health and government officials from the European Union, Italy, Japan, and United Kingdom recently convened to discuss how G7 countries must respond. GCOA today published a report detailing takeaways from the closed-door meeting, “The Role of G7 Governments in Global Efforts to Encourage Antimicrobial Development Through a Pull Incentive: Challenges and Collaboration.”

Kishida and Biden Face a Similar Demographic Crisis

Your front page story “Japan wrestles with age-old problem as population declines at record rate” (Report, April 13) and the letter in the same edition from Tim Hill, “A gently declining population is no reason to panic”, both describe what all societies face as they modernise in the 21st century.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.